Findings

What do systematic reviews say?

40 questions · 40 findings · 5 reviews · Hypertension

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 2.5%GRADE not reported 0 · 0%Very low 4 · 10%Low 21 · 52.5%Moderate 14 · 35%High 0 · 0%

Nonselective beta‐blockers vs placebo

SBP (mmHg) · adults with primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of nonselective beta‐blockers for primary hypertension 2014 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 948 participants
Low

Nonselective beta‐blockers vs placebo

Diastolic blood pressure · adults with primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of nonselective beta‐blockers for primary hypertension 2014 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 948 participants
Low

Nonselective beta‐blockers vs placebo

Heart rate · adults with primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of nonselective beta‐blockers for primary hypertension 2014 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 864 participants
Low

Nonselective beta‐blockers vs placebo

Pulse pressure · adults with primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of nonselective beta‐blockers for primary hypertension 2014 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 948 participants
Very low

Nonselective beta‐blockers vs placebo

Withdrawals due to adverse events · adults with primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of nonselective beta‐blockers for primary hypertension 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 729 participants
Low

Beta‐blockers with partial agonist activity vs no treatment

Variation in the decrease in 24‐hour ambulatory hourly SBP (at 3 to 12 weeks) · Men and non‐pregnant women ≥ 18 years old with essential hypertension

1 finding from 1 review

Time course for blood pressure lowering of beta‐blockers with partial agonist activity 2020 · Cochrane Headline outcomes only
no estimate extracted
121 participants
Very low

Beta‐blockers with partial agonist activity vs no treatment

Variation in the decrease in 24‐hour ambulatory hourly DBP (at 3 to 12 weeks) · Men and non‐pregnant women ≥ 18 years old with essential hypertension

1 finding from 1 review

Time course for blood pressure lowering of beta‐blockers with partial agonist activity 2020 · Cochrane Headline outcomes only
no estimate extracted
121 participants
Very low

Beta‐blockers with partial agonist activity vs no treatment

Variation in the decrease in 24‐hour ambulatory hourly HR (at 3 to 12 weeks) · Men and non‐pregnant women ≥ 18 years old with essential hypertension

1 finding from 1 review

Time course for blood pressure lowering of beta‐blockers with partial agonist activity 2020 · Cochrane Headline outcomes only
no estimate extracted
71 participants
Very low

First‐line thiazides vs beta‐blocker

Total mortality Duration: 1 to 5.8 years · patients with hypertension

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 18241 participants
Moderate

First‐line thiazides vs beta‐blocker

Total serious adverse events · patients with hypertension

The review found no eligible studies for this question.

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

First‐line thiazides vs beta‐blocker

Cardiovascular events · patients with hypertension

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 18135 participants
Moderate

First‐line thiazides vs beta‐blocker

Stroke · patients with hypertension

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 18135 participants
Low

First‐line thiazides vs beta‐blocker

Total CHD Duration: 1 to 5.8 years · patients with hypertension

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 18135 participants
Low

First‐line thiazides vs beta‐blocker

Congestive heart failure · patients with hypertension

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 6569 participants
Low

First‐line thiazides vs beta‐blocker

Adverse effects (side effects; treatment withdrawals) · patients with hypertension

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 18501 participants
Moderate

RAS inhibitors vs beta‐blocker

All‐cause death · patients with hypertension

RAS inhibitors showed no clear difference in all‐cause death compared with beta‐blockers (low certainty).

1 finding from 1 review

First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
RR 0.89 [0.78, 1.01]
1 study · 9193 participants
Low

RAS inhibitors vs beta‐blocker

Cardiovascular events · patients with hypertension

RAS inhibitors may leads to lower total cardiovascular events compared with beta‐blockers (low certainty).

1 finding from 1 review

First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
RR 0.88 [0.8, 0.98]
2 studies · 9239 participants
Low

RAS inhibitors vs beta‐blocker

Heart failure · patients with hypertension

RAS inhibitors showed no clear difference in total heart failure compared with beta‐blockers (low certainty).

1 finding from 1 review

First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
RR 0.95 [0.76, 1.18]
1 study · 9193 participants
Low

RAS inhibitors vs beta‐blocker

Myocardial infarction · patients with hypertension

RAS inhibitors showed no clear difference in total myocardial infarction compared with beta‐blockers (low certainty).

1 finding from 1 review

First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
RR 1.05 [0.86, 1.27]
2 studies · 9239 participants
Low

RAS inhibitors vs beta‐blocker

Stroke · patients with hypertension

RAS inhibitors may leads to lower total stroke compared with beta‐blockers (low certainty).

1 finding from 1 review

First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
RR 0.75 [0.63, 0.88]
1 study · 9193 participants
Low